PET scan to check treatment response in breast cancer
Part of Cancer, Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This trial uses a special PET scan to see how well your breast cancer is responding to neoadjuvant therapy (treatment given before surgery). The goal is to help doctors personalize your care by checking if the cancer is shrinking.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 16 and 65 years old.
- You have invasive breast cancer in one breast that is at least 2 cm and has spread to your armpit lymph nodes.
- You are scheduled to have neoadjuvant therapy (chemotherapy or other treatment before surgery).
- Your health is good overall, with normal blood cell counts and kidney and liver function.
- You have not had chemotherapy, hormone therapy, targeted therapy, or radiation for any reason before this study.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new type of PET/MRI scan can help doctors see how well breast cancer treatment is working. It is a platform study, meaning it can evaluate different treatments, but the focus is on using this advanced imaging to monitor response.
This study uses a special PET scan (68Ga FAPI) to check if lymph nodes under the arm still have cancer after you finish pre-surgery treatment. It helps doctors see how well the treatment worked before you have surgery.
This trial tests a special PET scan (68Ga-grazytracer) to see if it can predict early whether immunotherapy is working in people with lung cancer that can be surgically removed. If successful, this scan could help doctors tailor treatment sooner.
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
This trial tests a new PET scan that uses a special tracer to find breast cancer that has spread. The scan may help doctors better see where the cancer is and guide treatment.
This trial tests a new imaging test (a special PET scan) that can see HER2 proteins in breast cancer tumors. It is for people who are already getting treatment before surgery to see if the scan helps doctors understand how well the therapy is working.
Hear when a new Breast Cancer Invasive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.